ABSTRACT
Zoledronic acid and ibandronic acid are used in preventing skeletal-related event (SRE) in multiple myeloma (MM).Both drugs were listed in the Indonesian formulary. There was no available head-to-head comparative study, hence theneed for a systematic review. The purpose of this systematic review was to describe the effectiveness of intravenouszoledronic and ibandronic acids in preventing SRE. The search for articles was conducted on accessible databases withthe potential to provide relevant research material such as PUBMED, EBSCOhost, and ScienceDirect. The articleswere limited to randomized controlled trials on both drugs in MM patients, published between 1980 and 2018. Theoutcomes were SRE, progression-free survival (PFS), overall survival (OS), and adverse event (AE). Thirteen articleswere selected. According to the results obtained, the effectiveness of zoledronic acid in preventing SRE was superiorto placebo or clodronic acid but not superior to denosumab and pamidronic acid. Ibandronic acid was not superior toplacebo or pamidronic acid. The effectiveness of both drugs in preventing SRE was directly proportional to PFS andOS. In conclusion, zoledronic acid was superior to ibandronic acid, but with more occurrence of AE. However, the AEcould be reduced by prolonging the duration of the drug use.